KNIN (nintedanib) for Pulmonary Fibrosis

KNIN (nintedanib) is an enhanced KinetiSol® reformulation of the approved drug Ofev®, with potential to be a safer treatment for pulmonary fibrosis. Ofev is linked to chronic diarrhea in over 62% of pulmonary fibrosis patients. KinetiSol is the only technology capable of enhancing Ofev to deliver comparable blood levels to Ofev tablets via sublingual delivery. Sublingual delivery of nintedanib promises to minimize gastrointestinal and liver toxicities.